Literature DB >> 3458712

Rapid quantitative determination of four anthracyclines and their main metabolites in human nucleated haematopoietic cells.

P A Speth, P C Linssen, J B Boezeman, J M Wessels, C Haanen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3458712     DOI: 10.1016/s0378-4347(00)80803-8

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  7 in total

1.  Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype.

Authors:  P A te Boekhorst; J van Kapel; M Schoester; P Sonneveld
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

3.  Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells.

Authors:  C Cullinane; S M Cutts; C Panousis; D R Phillips
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

4.  Quantitation of cell-associated doxorubicin by high-performance liquid chromatography after enzymatic desequestration.

Authors:  A Andersen; D J Warren; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM).

Authors:  R Raijmakers; P Speth; T de Witte; P Linssen; J Wessels; C Haanen
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.